VOLITIONRX LTD (VNRX) Stock Profile — Insider Trades & Financials

Revenue$447.0K

Net Income-$6.3M

EPS$-0.17

Market Cap$27.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Cameron Reynolds

CEO & Executive Director

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patientâs cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Employees: 75
Headquarters: Henderson, Nevada, United States
Website

⚡

Core Efficiency

ROE?

18.31%

ROA?

-90.87%

D/E Ratio?

-1.24

Op. Margin?

-1077.86%

📊

Profitability Ratios

Net Margin?

-1402.76%

Loading company sections...

VOLITIONRX LTD

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness